Cargando…

Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase

BACKGROUND: Follow-up care in breast cancer is still an issue of debate. Diagnostic methods are more sensitive, and more effective therapeutic options are now available. The risk of recurrence is not only influenced by tumour stage but also by the different molecular subtypes. This study was perform...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Gioia, D, Stieber, P, Schmidt, G P, Nagel, D, Heinemann, V, Baur-Melnyk, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453962/ https://www.ncbi.nlm.nih.gov/pubmed/25647014 http://dx.doi.org/10.1038/bjc.2015.8

Ejemplares similares

Whole-body imaging of the musculoskeletal system: the value of MR imaging
por: Schmidt, Gerwin P., et al.
Publicado: (2007)

Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging
por: Treitl, Karla M., et al.
Publicado: (2021)

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer
por: Ackland, S P, et al.
Publicado: (2005)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers
por: Wang, Hsin-Yao, et al.
Publicado: (2016)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer
por: Boeck, S, et al.
Publicado: (2013)

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
por: Hamaoka, T, et al.
Publicado: (2010)

Pan-cancer whole-genome analyses of metastatic solid tumours
por: Priestley, Peter, et al.
Publicado: (2019)

Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours
por: Nwosu, A C, et al.
Publicado: (2008)

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
por: Joensuu, H, et al.
Publicado: (2011)

Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours
por: Marrache, F, et al.
Publicado: (2007)

α-Fetoprotein and human chorionic gonadotrophin-β as prognostic markers in neuroendocrine tumour patients
por: Shah, T, et al.
Publicado: (2008)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Urological referral of asymptomatic men in general practice in England
por: Melia, J, et al.
Publicado: (2008)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
por: Jonasch, E, et al.
Publicado: (2008)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Stereotactic Body Radiotherapy for Metastatic and Recurrent Ewing Sarcoma and Osteosarcoma
por: Brown, Lindsay C., et al.
Publicado: (2014)

Diffusion-weighted and multiphase contrast-enhanced MRI as surrogate markers of response to neoadjuvant sunitinib in metastatic renal cell carcinoma
por: Bharwani, N, et al.
Publicado: (2014)

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

Macrophage Content in Subcutaneous Adipose Tissue: Associations With Adiposity, Age, Inflammatory Markers, and Whole-Body Insulin Action in Healthy Pima Indians
por: Ortega Martinez de Victoria, Emilio, et al.
Publicado: (2009)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
por: Giessen, C, et al.
Publicado: (2013)

Radiological staging in breast cancer: which asymptomatic patients to image and how
por: Barrett, T, et al.
Publicado: (2009)

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
por: Daly, Louise E, et al.
Publicado: (2017)

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)
por: Fosså, S D, et al.
Publicado: (2005)

Pan-cancer whole-genome comparison of primary and metastatic solid tumours
por: Martínez-Jiménez, Francisco, et al.
Publicado: (2023)

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
por: Piketty, A-C, et al.
Publicado: (2005)

How to define a cut-off value of tumour markers in haemodialysis patients?
por: Mercadal, Lucile, et al.
Publicado: (2009)

The relevance of RT–PCR markers for metastatic tumour cell detection
por: Chechlińska, M, et al.
Publicado: (2006)

Asymptomatic Construct Failure after Metastatic Spine Tumor Surgery: A New Entity or a Continuum with Symptomatic Failure?
por: Kumar, Naresh, et al.
Publicado: (2021)

Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour
por: Rimmer, Y, et al.
Publicado: (2011)

Colorectal Tumour Mucosa Microbiome Is Enriched in Oral Pathogens and Defines Three Subtypes That Correlate with Markers of Tumour Progression
por: Zwinsová, Barbora, et al.
Publicado: (2021)

The role of surgical margins in atypical Lipomatous Tumours of the extremities
por: Rauh, Jessica, et al.
Publicado: (2018)

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
por: Nicol, A J, et al.
Publicado: (2011)

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study
por: Bork, U, et al.
Publicado: (2015)

Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI
por: Schraml, C., et al.
Publicado: (2013)

Effects of Stochastic Resonance Whole-Body Vibration in Individuals with Unilateral Brain Lesion: A Single-Blind Randomized Controlled Trial: Whole-Body Vibration and Neuromuscular Function
por: Herren, Kaspar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2sviae22v7prpj5fcgqt0b87ev